Psychedelic-Assisted Therapy Poses Coverage and Implementation Questions for Medicaid Programs
As psychedelic-assisted therapies move toward FDA approval and market entry, Medicaid programs face emerging policy and operational questions around coverage criteria, administration protocols, and workforce requirements. These therapies, being developed for treatment-resistant depression and PTSD, differ from traditional pharmaceuticals in requiring intensive clinical supervision and specialized settings. Medicaid leaders must consider prior authorization frameworks, benefit design, provider network adequacy, and reimbursement models as these treatments enter the behavioral health landscape. Early planning is necessary given Medicaid's role as the largest payer of behavioral health services and the complex operational requirements these therapies will demand.